Bone Marrow Transplantation最新文献

{"title":"Racial and ethnic disparities in brain-to-vein time among patients receiving CD19 CAR-T cell therapy for relapsed/refractory DLBCL","authors":"Neela Easton, Anna Alperovich, Alexandra Gomez-Arteaga, Sebastian Mayer, Nora Chokr, Adrienne Phillips, Jingmei Hsu, Koen van Besien, Matthew Gromowsky, Matthew Lunning, Tsiporah Shore, Juliet Barker, Samuel Yamshon","doi":"10.1038/s41409-026-02964-4","DOIUrl":"10.1038/s41409-026-02964-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1450-1452"},"PeriodicalIF":5.1,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Institutional risk management for out-of-specification commercial CAR-T products","authors":"Ron Ram, Ronit R. Gold","doi":"10.1038/s41409-026-02986-y","DOIUrl":"10.1038/s41409-026-02986-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1444-1446"},"PeriodicalIF":5.1,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of blinatumomab for dermatomyositis/SLE overlap syndrome occurring after allogeneic hematopoietic stem cell transplant performed for acute lymphoblastic leukemia","authors":"Roberto Carta, Carmen Dolores De Luca, Valentina Bertaina, Stefania Gaspari, Pietro Merli, Daria Pagliara, Franco Locatelli","doi":"10.1038/s41409-026-02990-2","DOIUrl":"10.1038/s41409-026-02990-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1447-1449"},"PeriodicalIF":5.1,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis","authors":"Patrizia Chiusolo, Andrea Bacigalupo, Luca Castagna, Sabrina Giammarco, Federica Sora, Elisabetta Metafuni, Maria Assunta Limongiello, Eugenio Galli, Filippo Frioni, Simona Sica","doi":"10.1038/s41409-026-02953-7","DOIUrl":"10.1038/s41409-026-02953-7","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1441-1443"},"PeriodicalIF":5.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","authors":"Enrico Maffini, Myriam Labopin, Anna Maria Raiola, Didier Blaise, Stefania Bramanti, Simona Sica, Yener Koc, Mi Kwon, Maija Itäla-Remes, Massimo Martino, Lucía López Corral, Jiri Pavlu, Benedetto Bruno, Alexandros Spyridonidis, Bipin Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty","doi":"10.1038/s41409-026-02988-w","DOIUrl":"10.1038/s41409-026-02988-w","url":null,"abstract":"Adults with acute myeloid leukaemia (AML) receiving T-cell replete hematopoietic cell transplantation (HCT) from haploidentical donors are increasing. It is unknown whether a total body irradiation (TBI)-based regimen is associated with better survival than a chemotherapy (chemo)-based regimen. This is a retrospective analysis of AML patients in first complete remission who received a HCT from a haploidentical donor, from 2010 to 2022, reported to the ALWP of the EBMT database. Patients were divided into TBI vs. chemo-based regimens and stratified by transplant conditioning intensity (TCI): low (1–2) vs. intermediate/high (2.5–6). A total of 2309 patients (median age 56.8 years, range 18–82) were included. For patients with low TCI, multivariate analysis confirmed higher disease relapse with TBI (HR 1.49, 95% CI 1.03–2.16, p = 0.033) with respect to chemo, but lower NRM (HR 0.56, 95% CI 0.36–0.89, p = 0.013). In TCI intermediate/high, TBI was associated with a higher risk of NRM (HR 1.71, 95% CI 1.07–2.74, p = 0.026), inferior OS (HR 1.61, 95% CI 1.08–2.42, p = 0.02) and GRFS (HR 1.43, 95% CI 1.03–1.95, p = 0.034). The use of TBI in AML transplanted from haploidentical donors is feasible, although it does not appear to be associated with a survival advantage compared to chemotherapy-only regimens. Prospective clinical trials are warranted.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1368-1378"},"PeriodicalIF":5.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the adult EBMT risk score valid and relevant for hematopoietic stem cell transplantation in children acute leukemia?","authors":"F. Baleydier, J. E. Galimard, F. Bernard, F. Gonzales, A. Dalissier, A. Al-Seraihy, J.-H. Dalle, C. R. S. Uppugunduri, L. Zubarovskaya, M. Zecca, F. Locatelli, A. Kulagin, F. Fagioli, S. Robinson, A. Balduzzi, A. Biffi, Y. Chalandon, P. Bader, S. Corbacioglu, Krzysztof Kalwak, M. Ansari, on behalf of Paediatric Diseases Working Party (PDWP) of European Society for Blood and Marrow Transplantation (EBMT)","doi":"10.1038/s41409-026-02952-8","DOIUrl":"10.1038/s41409-026-02952-8","url":null,"abstract":"The EBMT risk score, incorporating five factors to estimate the risks associated with haematopoietic stem cell transplantation (HSCT) in adult patients, has not been validated in children. This study aims to assess this score in 9447 children undergoing allogeneic HSCT for acute lymphoblastic or myeloid leukemia (ALL/AML) between 2010 and 2021. Risk factors were coded according to the original EBMT score. In both ALL (n = 5774) and AML (n = 3673), only disease status and the time from diagnosis to HSCT significantly impacted all the outcomes in the multivariable analysis. The combination of female donors and male recipients did not affect overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and leukemia-free survival (LFS). Additionally, the prognostic impact of donor type was not evident; when viewed as two modalities, the impact of MSD versus non-MSD on different outcomes in ALL was inconsistent with those observed in AML. Consequently, in both ALL and AML, scores ranging from 3 to 5 significantly affected all outcomes, whereas a score of 2 did not significantly impact NRM or RI in AML. Therefore, this analysis demonstrates that the adult EBMT risk score is not entirely reliable in children with acute leukemia, highlighting the need for a new pediatric-specific prognostic score.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1361-1367"},"PeriodicalIF":5.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-026-02952-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning","authors":"Yuanyuan Ren, Ranran Zhang, Xia Chen, Xiaoyan Zhang, Yang Wan, Xiaolan Li, Xiaojuan Chen, Xiaofan Zhu, Fang Liu, Wenyu Yang, Ye Guo","doi":"10.1038/s41409-026-02978-y","DOIUrl":"10.1038/s41409-026-02978-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1434-1437"},"PeriodicalIF":5.1,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early inflammatory complications after haploidentical hematopoietic stem cell transplantation with post transplant cyclophosphamide for acute leukemia: a pediatric multicenter experience","authors":"Filomena Pierri, Francesca Bagnasco, Francesco Saglio, Franca Fagioli, Stefano Giardino, Sara Pestarino, Davide Leardini, Francesca Gottardi, Riccardo Masetti, Maura Faraci","doi":"10.1038/s41409-026-02976-0","DOIUrl":"10.1038/s41409-026-02976-0","url":null,"abstract":"Haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PTCy) is a viable option for patients lacking a matched donor. In this setting, early inflammatory complications (EICs), such as cytokine release syndrome (CRS) and engraftment syndrome (ES), represent significant complications. Their risk factors and clinical impact, particularly in pediatric populations, remain poorly defined. This multicenter, retrospective study analyzed 102 consecutive pediatric haplo-HCT with PTCy for acute leukemia. It aimed to define EICs incidence, risk factors, and transplantation outcomes. The incidence of EICs was 21.6%, 95% CI (14.7–30.5). Use of peripheral blood stem cells (PBSC) was the sole independent risk factor, OR = 5.1, 95% CI (1.3–19.8), p = 0.017. Notably, all patients who developed CRS started CNI therapy (tacrolimus in all cases) on day 5. While not increasing initial acute GvHD (aGvHD) frequency, EICs predicted poorer response to first-line aGvHD therapy (45.5% vs. 6.9% complete response, p = 0.011) and a significantly higher risk of chronic GvHD (cGvHD) (55.6% vs. 20.6%; OR = 4.8, p = 0.008). No effect was seen on relapse, non-relapse mortality, or survival. EICs are common after haplo-HCT with PTCy and primarily associated with PBSC use. They identify a high-risk subgroup with refractory aGvHD and markedly increased cGvHD risk, supporting preferential bone marrow use, intensified monitoring and potentially novel strategies for GvHD prevention and management.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1353-1360"},"PeriodicalIF":5.1,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience","authors":"Yi-Ge Shen, Si-Yuan Chen, Rong-Ji Mu, Hui-Ying Li, Li Wang, Shu Cheng, Peng-Peng Xu, Zhong Zheng, Lin-Di Zhao, Hui-Juan Zhong, Ming-Ci Cai, Yao-Hui Huang, Di Fu, Yu-Jia Huo, Wei Tang, Meng-Meng Ji","doi":"10.1038/s41409-026-02992-0","DOIUrl":"10.1038/s41409-026-02992-0","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1438-1440"},"PeriodicalIF":5.1,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-026-02992-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation","authors":"Enrico Maffini,&nbsp;Maud Ngoya,&nbsp;Mohamed Houhou,&nbsp;Malek Benakli,&nbsp;Babak Bahar,&nbsp;Mahmoud Aljurf,&nbsp;Khalid Halahleh,&nbsp;Regis Peffault de Latour,&nbsp;Igor-Wolfgang Blau,&nbsp;Andrew Clark,&nbsp;Catherine Flynn,&nbsp;Peter Pal Remenyi,&nbsp;Maria Losa Maroto,&nbsp;Ibrahim Yakoub-Agha,&nbsp;Henrik Sengeloev,&nbsp;Cristina Castilla-Llorente,&nbsp;Emma Nicholson,&nbsp;Urpu Salmenniemi,&nbsp;Radovan Vrhovac,&nbsp;Jakob Passweg,&nbsp;Matthias Eder,&nbsp;Etienne Daguindau,&nbsp;Alexandros Spyridonidis,&nbsp;Arnon Nagler,&nbsp;Fabio Ciceri,&nbsp;Mohamad Mohty","doi":"10.1038/s41409-026-02991-1","DOIUrl":"10.1038/s41409-026-02991-1","url":null,"abstract":"The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (n = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) n = 219, Bu-Flu (n = 1100), and Bu-cyclophosphamide (Cy) (n = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57–0.92, p = 0.008; HR 0.78, 95% CI 0.64–0.94, p = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, p = 0.02; HR 0.67, 95% CI 0.47–0.94, p = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63–0.95, p = 0.01), and TBF (HR 0.68, 95% CI 0.47–0.99, p = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 10","pages":"1343-1352"},"PeriodicalIF":5.1,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}